Previous 10 | Next 10 |
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd. sale to Pfizer on October 4, 2022 , and completed a public offeri...
Summary The lazy way to interpret the tech titans earnings reports last week is to say that Cloud Tech is over. It's not. We organize post market trading we call "fishing" we use it to try and acquire shares at the lowest prices. Alphabet, Amazon, and Microsoft will regain the...
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (the "Company" or "Biohaven") today announced...
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University PR Newswire Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including neurosc...
Biohaven ( NYSE: BHVN ) has priced upsized public offering of 25M of its common shares, at a public offering price of $10.50/common share. Underwriters are granted a 30-day option to purchase up to an additional 3.75M common shares. Offering is expected to close on Oct...
Biohaven ( NYSE: BHVN ) on Tuesday announced a public offering of 20M shares, sending its shares 5.2% lower after the bell. Underwriters will get a 30-day option to buy up to an additional 3M shares. Biohaven ( BHVN ) will use the net proceeds from the offering...
Biohaven Announces Launch of Public Offering of Common Shares PR Newswire NEW HAVEN, Conn. , Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") announced today that it has commenced a public offering of 20,000,000 of its common shares p...
Summary I wanted to focus on an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns. I attempt to explain these precipitous bear market rallies, and how we anticipate them. I also talk about a tactical shift...
Summary Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price. Inter...
Make it two days in a row of big gains for Biohaven Ltd. (NYSE: BHVN) . Shares of the drugmaker skyrocketed 47.7% on Wednesday as of the market close. On Tuesday, Biohaven stock jumped nearly 14% . The momentum is primarily due to the company's new beginning after being spun...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...